Direct oral anticoagulants; a review for the non-specialist

Thrombin inhibitors and direct factor Xa inhibitors represent a major breakthrough in the field of anticoagulation pharmacotherapy. These novel agents have replaced warfarin as the oral anticoagulant of choice in certain indications, as they possess equal or superior efficacy and better safety prof...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Thilina Gunawardena
Formato:	article
Lenguaje:	EN
Publicado:	PAGEPress Publications 2021
Materias:	DOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/fe609b572aae45f58e3bad1e170569c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe609b572aae45f58e3bad1e170569c7
record_format	dspace
spelling	oai:doaj.org-article:fe609b572aae45f58e3bad1e170569c72021-11-26T14:38:52ZDirect oral anticoagulants; a review for the non-specialist10.4081/hr.2021.92392038-83222038-8330https://doaj.org/article/fe609b572aae45f58e3bad1e170569c72021-11-01T00:00:00Zhttps://www.pagepress.org/journals/index.php/hr/article/view/9239https://doaj.org/toc/2038-8322https://doaj.org/toc/2038-8330 Thrombin inhibitors and direct factor Xa inhibitors represent a major breakthrough in the field of anticoagulation pharmacotherapy. These novel agents have replaced warfarin as the oral anticoagulant of choice in certain indications, as they possess equal or superior efficacy and better safety profiles. They have a quick onset of action, predictable pharmacokinetic properties and minimal drug and food interactions. So they do not require frequent blood monitoring and dose adjustments as with warfarin. Considering all the advantages, there seems to be a rapid increase in the number of patients who are started on these novel anticoagulants. In this review, we highlight the pharmacology of these direct oral anticoagulants and the evidence-based indications for their use. We aim to provide a clinical overview for the non-specialist who may be called upon to manage a patient who is currently on one of these novel anticoagulants. Thilina GunawardenaPAGEPress PublicationsarticleDOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulantsDiseases of the blood and blood-forming organsRC633-647.5ENHematology Reports, Vol 13, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	DOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	DOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants Diseases of the blood and blood-forming organs RC633-647.5 Thilina Gunawardena Direct oral anticoagulants; a review for the non-specialist
description	Thrombin inhibitors and direct factor Xa inhibitors represent a major breakthrough in the field of anticoagulation pharmacotherapy. These novel agents have replaced warfarin as the oral anticoagulant of choice in certain indications, as they possess equal or superior efficacy and better safety profiles. They have a quick onset of action, predictable pharmacokinetic properties and minimal drug and food interactions. So they do not require frequent blood monitoring and dose adjustments as with warfarin. Considering all the advantages, there seems to be a rapid increase in the number of patients who are started on these novel anticoagulants. In this review, we highlight the pharmacology of these direct oral anticoagulants and the evidence-based indications for their use. We aim to provide a clinical overview for the non-specialist who may be called upon to manage a patient who is currently on one of these novel anticoagulants.
format	article
author	Thilina Gunawardena
author_facet	Thilina Gunawardena
author_sort	Thilina Gunawardena
title	Direct oral anticoagulants; a review for the non-specialist
title_short	Direct oral anticoagulants; a review for the non-specialist
title_full	Direct oral anticoagulants; a review for the non-specialist
title_fullStr	Direct oral anticoagulants; a review for the non-specialist
title_full_unstemmed	Direct oral anticoagulants; a review for the non-specialist
title_sort	direct oral anticoagulants; a review for the non-specialist
publisher	PAGEPress Publications
publishDate	2021
url	https://doaj.org/article/fe609b572aae45f58e3bad1e170569c7
work_keys_str_mv	AT thilinagunawardena directoralanticoagulantsareviewforthenonspecialist
_version_	1718409329215799296

Direct oral anticoagulants; a review for the non-specialist

Ejemplares similares